Connecticut Wealth Management LLC Has $445,000 Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Connecticut Wealth Management LLC reduced its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 46.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,782 shares of the biopharmaceutical company's stock after selling 13,000 shares during the quarter. Connecticut Wealth Management LLC's holdings in TG Therapeutics were worth $445,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of TGTX. Bleakley Financial Group LLC bought a new position in TG Therapeutics in the 4th quarter valued at about $245,000. Castellan Group acquired a new stake in TG Therapeutics in the 4th quarter valued at about $8,539,000. Barclays PLC lifted its holdings in TG Therapeutics by 83.9% in the 3rd quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company's stock valued at $8,117,000 after acquiring an additional 158,323 shares during the last quarter. Stratos Wealth Advisors LLC acquired a new stake in TG Therapeutics in the 4th quarter valued at about $241,000. Finally, Strategic Financial Concepts LLC purchased a new stake in TG Therapeutics during the fourth quarter valued at about $1,404,000. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. HC Wainwright reaffirmed a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a research note on Tuesday, March 4th. Wall Street Zen raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, TG Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $40.80.

TG Therapeutics Stock Performance

TGTX stock traded down $0.18 during midday trading on Wednesday, hitting $35.06. The stock had a trading volume of 446,727 shares, compared to its average volume of 2,740,934. The firm has a market capitalization of $5.57 billion, a price-to-earnings ratio of -350.54 and a beta of 2.21. TG Therapeutics, Inc. has a 52 week low of $15.16 and a 52 week high of $46.48. The stock has a 50-day simple moving average of $37.84 and a 200 day simple moving average of $34.36. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.16). The firm had revenue of $120.86 million during the quarter, compared to the consensus estimate of $117.07 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm's revenue for the quarter was up 90.4% compared to the same quarter last year. During the same period last year, the business earned ($0.07) earnings per share. As a group, equities research analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.